Back to Search Start Over

Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study.

Authors :
Milgrom SA
Kim J
Pei Q
Lee I
Hoppe BS
Wu Y
Hodgson D
Kessel S
McCarten KM
Roberts K
Lo AC
Cole PD
Kelly KM
Cho SY
Source :
British journal of haematology [Br J Haematol] 2023 Jun; Vol. 201 (6), pp. 1192-1199. Date of Electronic Publication: 2023 Mar 15.
Publication Year :
2023

Abstract

The Children's Oncology Group AHOD0831 study used a positron emission tomography (PET) response-adapted approach in high-risk Hodgkin lymphoma, whereby slow early responders (SERs) received more intensive therapy than rapid early responders (RERs). We explored if baseline PET-based characteristics would improve risk stratification. Of 166 patients enrolled in the COG AHOD0831 study, 94 (57%) had baseline PET scans evaluable for quantitative analysis. For these patients, total body metabolic tumour volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUV <subscript>max</subscript> ) and peak SUV (SUV <subscript>peak</subscript> ) were obtained. MTV/TLG thresholds were an SUV of 2.5 (MTV <subscript>2.5</subscript> /TLG <subscript>2.5</subscript> ) and 40% of the tumour SUV <subscript>max</subscript> (MTV <subscript>40%</subscript> /TLG <subscript>40%</subscript> ). TLG <subscript>2.5</subscript> was associated with event-free survival (EFS) in the complete cohort (p = 0.04) and in RERs (p = 0.01), but not in SERs (p = 0.8). The Youden index cut-off for TLG <subscript>2.5</subscript> was 1841. Four-year EFS was 92% for RER/TLG <subscript>2.5</subscript>  up to 1841, 60% for RER/TLG <subscript>2.5</subscript>  greater than 1841, 74% for SER/TLG <subscript>2.5</subscript>  up to 1841 and 79% for SER/TLG <subscript>2.5</subscript>  greater than 1841. Second EFS for RER/TLG <subscript>2.5</subscript>  up to 1841 was 100%. Thus, RERs with a low baseline TLG <subscript>2.5</subscript> experienced excellent EFS with less intensive therapy, whereas RERs with a high baseline TLG <subscript>2.5</subscript> experienced poor EFS. These findings suggest that patients with a high upfront tumour burden may benefit from intensified therapy, even if they achieve a RER.<br /> (© 2023 British Society for Haematology and John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1365-2141
Volume :
201
Issue :
6
Database :
MEDLINE
Journal :
British journal of haematology
Publication Type :
Academic Journal
Accession number :
36922022
Full Text :
https://doi.org/10.1111/bjh.18734